Delving into the Latest Updates on Linrodostat with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Linrodostat (USAN), Linrodostat mesylate, BMS-986205

+ [5]

Target

IDO1

Mechanism

IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

CarcinosarcomaRecurrent Endometrial CancerUCS+ [3]

Inactive Indication

Advanced Malignant Solid NeoplasmLaryngeal DiseasesLymphoid Interstitial Pneumonia+ [9]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC24H24ClFN2O

InChIKeyKRTIYQIPSAGSBP-ZACQAIPSSA-N

CAS Registry1923833-60-6

Certain low‐level immune‐related adverse events (irAEs) have been associated with survival benefits in patients with various solid tumors on immune checkpoint inhibitors (ICIs). We aimed to investigate the association between irAEs and response to neoadjuvant ICIs in patients with head and neck squamous cell carcinoma (HNSCC) and to identify differences in circulating cytokine levels based on irAE status.

Methods:

This was a retrospective cohort study including three neoadjuvant clinical trials from July 2017 to January 2022: NCT03238365 (nivolumab ± tadalafil), NCT03854032 (nivolumab ± BMS986205), NCT03618654 (durvalumab ± metformin). The presence and type of irAEs, pathologic treatment response, and survival were compared. Canonical linear discriminant analysis (LDA) was performed to identify combinations of circulating cytokines predictive of irAEs using plasma sample multiplex assay.

Results:

Of 113 participants meeting inclusion criteria, 32 (28.3%) developed irAEs during treatment or follow‐up. Positive p16 status was associated with irAEs (odds ratio [OR] 2.489; 95% CI 1.069–6.119; p = 0.043). irAEs were associated with pathologic treatment response (OR 3.73; 95% CI 1.34–10.35; p = 0.011) and with higher OS in the combined cohort (HR 0.319; 95% CI 0.113–0.906; p = 0.032). Patients with irAEs within the nivolumab cohort had significant elevations of select cytokines pre‐treatment. Canonical LDA identified key drivers of irAEs among all trials, which were highly predictive of future irAE status.

Conclusions:

irAEs are associated with response to neoadjuvant ICI therapy in HNSCC and can serve as clinical indicators for improved clinical outcomes. irAEs can be predicted by concentrations of several circulating cytokines prior to treatment.

01 Apr 2024·Biomaterials

Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy

Article

Author: Li, Wenpan ; Kim, Minhyeok ; Chung, Jinha ; Scott, Aaron James ; Lu, Jianqin ; Tran, Tuyen Ba ; Jiang, Yanhao ; Wang, Zhiren

Camptothesome is a sphingomyelin-conjugated camptothecin (SM-CSS-CPT) nanovesicle that fortified the therapeutic delivery of CPT in diverse cancer types. To mitigate the Camptothesome-induced IDO1 negative feedback mechanism, we had co-encapsulated, indoximod (IND, IDO1 inhibitor) into Camptothesome using doxorubicin-derived IND (DOX-IND). To maximize the therapeutic potential of DOX-IND/Camptothesome, herein, we first dissected the synergistic drug ratio (DOX-IND/SM-CSS-CPT) via systematical in vitro screening. DOX-IND/Camptothesome with optimal drug ratio synchronized in vivo drug delivery with significantly higher tumor uptake compared to free drugs. This optimum DOX-IND/Camptothesome outperformed the combination of Camptothesome, Doxil and IND or other IDO1 inhibitors (BMS-986205 or epacadostat) in treating mice bearing late-stage MC38 tumors, and combination with immune checkpoint blockade (ICB) enabled it to eradicate 60 % of large tumors. Further, this optimized co-delivery Camptothesome beat Folfox and Folfiri, two first-line combination chemotherapies for colorectal cancer in antitumor efficacy and exhibited no side effects as compared to the severe systemic toxicities associated with Folfox and Folfiri. Finally, we demonstrated that the synergistic DOX-IND/Camptothesome was superior to the combined use of Onivyde + Doxil + IND in curbing the advanced orthotopic CT26-Luc tumors and eliminated 40 % tumors with complete metastasis remission when cooperated with ICB, eliciting stronger anti-CRC immune responses and greater reversal of immunosuppression. These results corroborated that with precise optimal synergistic drug ratio, the therapeutic potential of DOX-IND/Camptothesome can be fully unleased, which warrants further clinical investigation to benefit the cancer patients.

01 Feb 2024·Investigational new drugs

Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma

Article

Author: Huynh, Jasmine C ; Garcia, Leslie ; Kim, Edward J ; Cho, May ; Singh, Amisha ; Al-Obeidi, Ebaa ; Monjazeb, Arta ; Tam, Kit ; Martinez, Anthony ; Lara, Frances

Abstract:

Background:

Indoleamine-2,3-dioxygenase (IDO) helps orchestrate immune suppression and checkpoint inhibitor resistance in hepatocellular carcinoma (HCC). BMS-986,205 is a novel oral drug that potently and selectively inhibits IDO. This Phase I/II study evaluated the safety and tolerability of BMS-986,205 in combination with nivolumab as first-line therapy in advanced HCC.

Methods:

Adults with untreated, unresectable/metastatic HCC received BMS-986,205 at two dose levels (50–100 mg orally daily) in combination with fixed dose nivolumab (240mg/m2 IV on Day 1 of each 14-day cycle). The primary objective was to determine the safety and tolerability of this combination; secondary objectives were to obtain preliminary efficacy.

Results:

Eight patients received a total of 91 treatment cycles in the dose escalation phase. All patients were Child Pugh A and 6 patients had underlying viral hepatitis. In the 6 evaluable patients, no dose-limiting toxicities (DLTs) were observed. The most common treatment-related adverse events (TRAEs) were aspartate transaminase (AST) and alanine transaminase (ALT) elevation (3 patients) and diarrhea, maculopapular rash and increased alkaline phosphatase (2 patients each). Grade 3 events were diarrhea and AST elevation (1 patient), and hyperglycemia and pancreatitis requiring treatment discontinuation (1 patient). No grade 4–5 events occurred. Partial response was observed in 1 patient (12.5%) and stable disease in 3 patients (37.5%), yielding a disease control rate of 50%. Median PFS was 8.5 weeks; median OS was not reached.

Conclusion:

Combination BMS-986,205 and nivolumab showed a manageable safety profile with durable benefit as first-line therapy in a meaningful subset of advanced HCC patients.

3

News (Medical) associated with Linrodostat

28 Nov 2022

·www.businesswire.com

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering. This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets. Business Questions: How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer? Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward? What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer? Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity? If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor? Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC? Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why? How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent? If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC? What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed? For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl

Phase 2VaccineImmunotherapyClinical ResultASCO

09 Feb 2021

·www.globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade. “Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights: Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder's inner surface, wherein the bladder muscle is not involved. NMIBC Pipeline Therapies Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030. BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024. UGN-102: UroGen Pharma UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023. Atezolizumab: Hoffmann-La Roche Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028. To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report Scope of Non-Muscle Invasive Bladder Cancer Pipeline Report Coverage: Global Major Players: 30+ companiesProminent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBioKey Drugs: 30+ pipeline drugsNon-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202Phases Targets Mechanism of Action Molecule Types Route of Administration Product Types Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain. Table of Contents Related Reports Bladder Cancer Market DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bladder cancer, historical and forecasted epidemiology as well as the Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Muscle Invasive Bladder Cancer Market DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer Non-Muscle Invasive Bladder Cancer Market DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Multiple Myeloma Market DelveInsight’s ‘Multiple Myeloma (MM) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China. Non-Small Cell Lung Cancer Market DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Prostate Cancer Market DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adenoid Cystic Carcinoma Market DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Liver Cancer Market DelveInsight's "Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Pancreatic Cancer Market DelveInsight's "Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Advanced Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Pancreatic Adenocarcinoma Market DelveInsight's "Pancreatic Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CollaborateAntibody

27 Jan 2021

·www.globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade. “Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights: Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder's inner surface, wherein the bladder muscle is not involved. NMIBC Pipeline Therapies Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030. BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024. UGN-102: UroGen Pharma UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023. Atezolizumab: Hoffmann-La Roche Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028. To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report Scope of Non-Muscle Invasive Bladder Cancer Pipeline Report Coverage: Global Major Players: 30+ companiesProminent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBioKey Drugs: 30+ pipeline drugsNon-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202Phases Targets Mechanism of Action Molecule Types Route of Administration Product Types Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain. Table of Contents Related Reports Bladder Cancer Market DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bladder cancer, historical and forecasted epidemiology as well as the Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Muscle Invasive Bladder Cancer Market DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer Non-Muscle Invasive Bladder Cancer Market DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Multiple Myeloma Market DelveInsight’s ‘Multiple Myeloma (MM) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China. Non-Small Cell Lung Cancer Market DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Prostate Cancer Market DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adenoid Cystic Carcinoma Market DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Liver Cancer Market DelveInsight's "Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Pancreatic Cancer Market DelveInsight's "Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Advanced Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Pancreatic Adenocarcinoma Market DelveInsight's "Pancreatic Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CollaborateAntibody

100 Deals associated with Linrodostat

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11412	-	-	DB14986

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	US	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	JP	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	AU	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	AT	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	BR	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	CA	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	CZ	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	FR	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	DE	Bristol Myers Squibb Co.	24 May 2018
Non-Small Cell Lung Cancer	Phase 3	GR	Bristol Myers Squibb Co.	24 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03695250 (CTgov)	Phase 1/2	Unresectable Hepatocellular Carcinoma \| Metastatic hepatocellular carcinoma	8	nivolumab+IDO1 Inhibitor BMS-986205	wophniokew(qyiiagnzkh) = egycpjymud yuqgdwuxmz (jgpakecpdm, gfbzqxvgkc - gxavxhjbtb) View more	-	22 Aug 2023
NCT03519256 (CheckMate 9UT, CTgov)	Phase 2	Non-Muscle Invasive Bladder Neoplasms	142	Nivolumab (Arm A: Nivolumab)	sxtlcxwaza(bpahyyzvvh) = zdcralbwvq fmaasooeuk (ctethwckrm, bfsdrtpcbf - srsvufncwe) View more	-	01 Jun 2023
NCT03519256 (CheckMate 9UT, CTgov)	Phase 2	Non-Muscle Invasive Bladder Neoplasms	142	BCG+Nivolumab (Arm B: Nivolumab Plus Intravesical BCG)	sxtlcxwaza(bpahyyzvvh) = bpnhzzeeme fmaasooeuk (ctethwckrm, uwkaykbaif - hhywhvtwqv) View more	-	01 Jun 2023
NCT03854032 (CA017-087, ASCO2022) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck Neoadjuvant	42	nivolumab	qprlweayoz(uizvupekbt) = dqquzbaxok uscqkuhuwy (btceawmuwk )	Non-superior	02 Jun 2022
NCT03854032 (CA017-087, ASCO2022) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck Neoadjuvant	42	Nivolumab+Linrodostat	qprlweayoz(uizvupekbt) = gymjxaowni uscqkuhuwy (btceawmuwk )	Non-superior	02 Jun 2022
NCT03695250 (ASCO2022)	Phase 1/2	Hepatocellular Carcinoma First line	8	BMS-986205 + Nivolumab	vzjtxjxxhd(imikdhlqju) = mzywaabzgw qqjjrxhbog (aagmkcthdh ) View more	Positive	02 Jun 2022
NCT04106414 (CA017-056, ASCO2022)	Phase 2	Recurrent Endometrial Cancer Maintenance	24	Nivolumab + BMS-986205	bhwwumevml(hjtfhjdwor) = Treatment-related adverse events (TRAEs) grade ≥ 3 in the NIVO arm included acute kidney injury (n = 1, 8.3%), hypokalemia (n = 1, 8.3%), and thromboembolic event (n = 1, 8.3%). In the NIVO + IDO arm, TRAEs grade ≥ 3 included fatigue (n = 1, 8.3%), and elevated liver function (n = 1, 8.3%). No TRAEs led to study-drug interruption or dose reductions. dhfttnktgv (brwyjanfcv )	Negative	02 Jun 2022
NCT03792750 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm \| Advanced cancer	12	Nivolumab+BMS-986205 (BMS-986205 in Combination With Nivolumab)	oznxwcpymq(ieiemnvweu) = crupomjqbh cbefiliyli (wesyrqtfbu, fhuhkjjcah - evtgvsjusb) View more	-	28 Feb 2022
NCT03792750 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm \| Advanced cancer	12	Nivolumab+BMS-986205 (BMS-986205 Monotherapy and in Combination With Nivolumab)	exncbzoekm(hmkndnkpiv) = oycsgkwdgv iljqpoyeru (erbeuoozgu, awqbzakobp - vnmvjecyhg) View more	-	28 Feb 2022
NCT03329846 (CTgov)	Phase 3	Unresectable Melanoma	20	Nivolumab+BMS-986205	wxjszmfciu(kihyhzjccg) = puvmzgtevf dsmjfqxbcc (ardtvpmyet, yfobcoxekz - jdffycyumz) View more	-	09 Jul 2021
NCT02658890 (ASCO_GU2019) Manual	Phase 1/2	Bladder Cancer	516	BMS-986205+nivolumab	savqzabfui(mqodkgffbo) = ufhmrysmwm nkeeovtacu (zwaldzufzr ) View more	Positive	15 Feb 2019
NCT02658890 (BMS-986205, SITC2017)	Phase 1/2	Advanced cancer kynurenine	216	BMS-986205 100 mg + Nivolumab 240 mg	ljgcyflywh(pkbjrcbrji) = thbzfqhkau sdgldbcyho (dcdwtemhyv ) View more	Positive	07 Dec 2017
NCT02658890 (BMS-986205, SITC2017)	Phase 1/2	Advanced cancer kynurenine	216	BMS-986205 200 mg + Nivolumab 480 mg	ljgcyflywh(pkbjrcbrji) = plvhchmbew sdgldbcyho (dcdwtemhyv ) View more	Positive	07 Dec 2017